Details for Patent: 9,258,035
✉ Email this page to a colleague
Which drugs does patent 9,258,035 protect, and when does it expire?
Patent 9,258,035 protects ABILIFY MYCITE KIT and is included in one NDA.
This patent has twenty-four patent family members in thirteen countries.
Summary for Patent: 9,258,035
Title: | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Abstract: | A device including an integrated circuit, a partial power source, including first and second materials associated with the integrated circuit is disclosed. The first and second materials are configured to provide a voltage potential difference when in contact with a conductive fluid to power up the device. A signal amplification element secured around the integrated circuit relative to the first and second materials is configured to facilitate extension of a current flow path between the first and second materials. A modulator is configured to control conductance between the first and second materials to generate a detectable signal that is partially defined by the current flow extending through the conductive fluid. A communication module is coupled to the partial power source and is configured to communicate with a receiver and an antenna electrically coupled to the communication module, which uses the antenna to communicate with the receiver. |
Inventor(s): | Robertson; Timothy (Belmont, CA), Zdeblick; Mark (Portola Valley, CA) |
Assignee: | Proteus Digital Health, Inc. (Redwood City, CA) |
Application Number: | 14/699,809 |
Patent Claim Types: see list of patent claims | Device; |
Drugs Protected by US Patent 9,258,035
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-001 | Nov 13, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-002 | Nov 13, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-003 | Nov 13, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Otsuka | ABILIFY MYCITE KIT | aripiprazole | TABLET;ORAL | 207202-004 | Nov 13, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,258,035
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2009221781 | ⤷ Try a Trial | |||
Canada | 2717862 | ⤷ Try a Trial | |||
China | 102014867 | ⤷ Try a Trial | |||
China | 104376659 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |